On Jun 30, 2021 ArriVent Biopharma closed a Series A round and raised $90,000,000 from Boyu Capital, Hillhouse Capital Group, Lilly Asia Ventures, Lyra Capital, Octagon Capital Advisors, OrbiMed, featuring lead investors Hillhouse Capital Group.

About the company: ArriVent Biopharma is located in Philadelphia, the United States, North America. “ArriVent Biopharma is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep, global network of biotechs and big Pharmas, ArriVent has access to drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with biopharma companies, ArriVent aims to globalize medicines for patients with a broad range of diseases, with an initial focus in oncology.”

Company website: arrivent.com/